Skip to main content
SpringerLink
Log in

Systemic Therapy for Inflammatory Breast Cancer

  • Chapter
  • First Online:
Breast Disease

  • 861 Accesses

Abstract

Inflammatory breast carcinoma (IBC) is the most aggressive, lethal, and rare form of breast cancer. IBC is characterized by the rapid development of erythema, edema, and peau d’orange over a third or more of the skin of the breast due to the occlusion of dermal mammary lymphatics by tumor emboli. IBC is associated with rapid progression, with a high risk of axillary lymph node involvement and distant metastases at initial diagnosis. The most striking progress in the management of IBC has been the sequential incorporation of preoperative systemic chemotherapy [an induction regimen containing an anthracycline and a taxane (plus trastuzumab in HER2-positive patients)], followed by surgery and radiation therapy. This multidisciplinary approach has essentially transformed IBC from a uniformly fatal disease with 5-year overall survival rates of less than 5% to one in which 5-year overall survival rates range from 46% to 61% and 15-year survival rates vary between 20% and 30%. The response to primary chemotherapy is a strong indicator of survival. The 15-year survival rate is 44% in patients who achieve a pathological complete response after primary chemotherapy. In this chapter, preoperative systemic therapy for the disease is discussed after a brief outline of inflammatory breast carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Barsky SH, Mrozek E, Love R. Inflammatory breast cancer. In: Bland KI, Copeland III EM, editors. The breast comprehensive management of benign and malignant diseases. 4th ed. Philadelphia: Saunders; 2009. p. 1393–402.

    Google Scholar 

  2. Dean-Colomb WM, Cristofanilli M. Inflammatory breast cancer. In: Kantarjian HM, Wolff RA, Koller CA, editors. The MD Anderson manual of medical oncology. 2nd ed. China: Mc Graw-Hill; 2011. p. 712–29.

    Google Scholar 

  3. Woodward WE, Cristofanilli M. Inflammatory breast cancer. Semin Radiat Oncol. 2009;19:256–65.

    Article  PubMed  Google Scholar 

  4. Overmoyer B, Pierce LJ. Inflammatory breast cancer. In: Harris JR, Morrow M, Osborne JK, editors. Disease of the breast. 5th ed. Philadelphia: Wolters Kluwer; 2015. p. 800–15.

    Google Scholar 

  5. Yamauchı H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012;17:891–9.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lee BJ, Tannenbaum NE. Inflammatory carcinoma of the breast; report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet. 1924;39:580–95.

    Google Scholar 

  7. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515–23.

    Article  CAS  PubMed  Google Scholar 

  8. Rabban J. Breast. In: Edge SB, Byrd DB, Compton CC, Fritz AG, Grene FI, Trotti A, editors. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2010. p. 345–77.

    Google Scholar 

  9. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guideline in oncology. Breast Cancer. 2018. www.nccn.org.

  10. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. Cancer. 2011;117:1819–26.

    Article  PubMed  Google Scholar 

  11. Hirko KA, Soliman AS, Banerjee M, Ruterbusch J, Harford JB, Merajver SD, et al. A comparison of criteria to identify inflammatory breast cancer cases from medical records and the surveillance, epidemiology and end results data base. 2007–2009. Breast J. 2014;20:185–91.

    Article  PubMed  Google Scholar 

  12. Levine PH, Venerosa C. The epidemiology of inflammatory breast cancer. Semin Oncol. 2008;35:11–6.

    Article  PubMed  Google Scholar 

  13. Dawood S, Cristofanilli M. What progress have we made in managing inflammatory breast cancer? Oncology (Willingston Park). 2007;21:673–9.

    Google Scholar 

  14. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;22:9–23.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–75.

    Article  PubMed  Google Scholar 

  16. Wingo PA, Jamison PM, Young JL, Gargiullo P. Population- based statistics for women diagnosed with inflammatory breast cancer. Cancer Causes Control. 2004;15:321–8.

    Article  PubMed  Google Scholar 

  17. Corbex M, Bouzbid S, Boffetta P. Features of breast cancer in developing countries, examples from North-Africa. Eur J Cancer. 2014;50:1808–18.

    Article  PubMed  Google Scholar 

  18. Slaoui M, Razine R, İbrahimi A, Attaleb M, Mzibri ME, Amrani M. Breast cancer in Morocco: a literature review. Asian Pac J Cancer. 2014;15:1067–74.

    Article  Google Scholar 

  19. Chiedozi LC. Rapidly progressing breast cancer in Nigeria. Eur J Surg Oncol. 1987;13:505–9.

    CAS  PubMed  Google Scholar 

  20. Maalej M, Frikha H. Ben Salem, Daoud J, Bouaouina N, Ben Abdallah M, et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer. 1999;86:302–6.

    CAS  PubMed  Google Scholar 

  21. Gunhan BI, Üstün EE, Memiş A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical and pathologic findings in 142 cases. Radiology. 2002;223:929–38.

    Google Scholar 

  22. Amparo RS, Angel CD, Ana LH, Antonio LC, Vicente MS, Carlos FM, et al. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat. 2000;64:269–73.

    Article  CAS  PubMed  Google Scholar 

  23. Natori A, Hayashi N, Soejima K, Deshpande GA, Takahashi O, Cristofanilli M, et al. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. Clin Breast Cancer. 2013;13:460–4.

    Article  PubMed  Google Scholar 

  24. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body-mass index. J Clin Oncol. 1998;16:3731–5.

    Article  CAS  PubMed  Google Scholar 

  25. Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat. 2000;64:157–63.

    Article  CAS  PubMed  Google Scholar 

  26. Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, Buist DS, et al. Risk factors for inflammatory breast cancer and other invasive breast cancer. J Natl Cancer Inst. 2013;105:1373–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mohamed MM, Al-raawi D, Sabet SF, El-Shinawi M. Inflammatory breast cancer: new factors contribute to disease etiology: review. J Adv Res. 2013;6:526–35.

    Google Scholar 

  28. Levine PH, Mourali N, Tabbane F, Loon J, Terasaki P, Tsang P, et al. Studies on the role of cellular immunity and genetics in the etiology of rapidly progressing breast cancer in Tunisia. Int J Cancer. 1981;27:611–5.

    Article  CAS  PubMed  Google Scholar 

  29. Mourali N, Levine PH, Tabanne F, Belhassen S, Bahi J, Bennaceur M, et al. Rapidly progressing breast cancer (poussee evolutive) in Tunisia: studies on delayed hypersensitivity. Int J Cancer. 1978;22:1–3.

    Article  CAS  PubMed  Google Scholar 

  30. Pogo BG, Holland JF, Levine PH. Human mammary tumor virus in inflammatory breast cancer. Cancer. 2010;116(11 suppl):2741–4.

    Article  PubMed  Google Scholar 

  31. Levine PH, Pogo BG, Klouj A, Coronel S, Woodson K, Melana SM, et al. Increasing evidence for a human breast carcinoma virus with geographic differences. Cancer. 2004;101:721–6.

    Article  PubMed  Google Scholar 

  32. El-Shinawi M, Mohamed HT, El-Ghonaimy EA, Tantawy M, Younis A, Schneider RJ, et al. Human cytomegalovirus infection enhances NF/kB/p65 signaling in inflammatory breast cancer patients. PLoS One. 2013;8:1–10.

    Article  CAS  Google Scholar 

  33. Gutierrez-Barrera AM, Turco DL, Alvarez RH, Litton JK, Valero V, Hortobagyi GN, et al. BRCA mutations in women with inflammatory breast cancer. J Clin Oncol. 2010;(ASCO breast cancer symposium abstracts) 28:Abstract 192.

    Google Scholar 

  34. Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, et al. BRCA mutations in women with inflammatory breast cancer. Cancer. 2018;24:466–74.

    Article  CAS  Google Scholar 

  35. Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 2001;7:398–404.

    Article  CAS  PubMed  Google Scholar 

  36. Ueno NT, Fernandez JRE, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, et al. International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018;9:1437–47.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis. 2005;22:45–54.

    Article  PubMed  Google Scholar 

  38. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography and ultrasonography findings. Breast Cancer Res Treat. 2008;109:417–26.

    Article  CAS  PubMed  Google Scholar 

  39. Iacconi C, Galman L, Zheng J, Sacchini V, Sutton EJ, Dershaw D, et al. Multicentric cancer detected at breast MR imaging and not all mammography: important or not? Radiology. 2016;279:378–84.

    Article  PubMed  Google Scholar 

  40. Schairer C, Brown LM, Mai PL. Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparable staged non-inflammatory breast cancer. Breast Cancer Res Treat. 2011;129:117–24.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Morgensztern D. Breast pathology. In: Silva OE, Zurrida S, editors. Breast cancer, a practical guide. 3rd ed. Edinburgh: Elsevier; 2005. p. 84–94.

    Google Scholar 

  42. Stamatakos MD. Invasive breast cancer. In: Jacops L, Finlayson CA, editors. Early diagnosis and treatment of cancer: breast cancer. Philadelphia: Saunders-Elsevier; 2011. p. 21–54.

    Chapter  Google Scholar 

  43. Abner A, Kaufman M, Pories S, Gauvin G. Unusual presentations of malignancy. Case 1. Male inflammatory (?) breast cancer. J Clin Oncol. 2001;19:3288–9.

    Article  CAS  PubMed  Google Scholar 

  44. Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, İbrahim NK. Inflammatory breast cancer: a distinct clinicopathological entity transcending histological distinction. PLoS One. 2016;11(1):1–11.e0145534. https://doi.org/10.1371/journal.pone.0145534.

    Article  CAS  Google Scholar 

  45. Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer. 1978;41:1595–605.

    Article  CAS  PubMed  Google Scholar 

  46. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011;16:1675–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancer. Breast Cancer Res. 2013;15:R112 (1–9).

    Article  CAS  Google Scholar 

  48. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 2004;64:8558–65.

    Article  CAS  PubMed  Google Scholar 

  49. Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, et al. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat. 2013;138:761–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Bertucci F, Finetti P, Birnbaum D, Viens P. Gene expression profiling of inflammatory breast cancer. Cancer. 2010;116(11 suppl):2783–93.

    Article  CAS  PubMed  Google Scholar 

  51. Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am J Cancer. 1938;33:33–49.

    Article  Google Scholar 

  52. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 2005;22:67–73.

    Article  PubMed  Google Scholar 

  53. Bruckman JE, Harris JR, Levene MB, Chaffey JT, Hellman S. Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer. 1979;43:985–93.

    Article  CAS  PubMed  Google Scholar 

  54. Perez CA, Fields JN. Role of radiation therapy for locally advanced and inflammatory carcinoma of the breast. Oncology (Huntingt). 1979;1:81–94.

    Google Scholar 

  55. Barker JL, Nelson AJ, Montague ED. Inflammatory carcinoma of the breast. Radiology. 1976;121:173–6.

    Article  CAS  PubMed  Google Scholar 

  56. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg. 1994;18:87–92.

    Article  CAS  PubMed  Google Scholar 

  57. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8:141–8.

    Article  CAS  PubMed  Google Scholar 

  58. Giordano SH. Update on locally advanced breast cancer. Oncologist. 2003;8:521–30.

    Article  PubMed  Google Scholar 

  59. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200–8.

    Article  PubMed  Google Scholar 

  60. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067–74.

    Article  CAS  PubMed  Google Scholar 

  61. Sinclair S, Swain SM. Primary systemic chemotherapy for inflammatory breast cancer. Cancer. 2010;116(11 suppl):2821–8.

    Article  CAS  PubMed  Google Scholar 

  62. Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, et al. Survival of women with inflammatory breast cancer : a large population-based study. Ann Oncol. 2014;25:1143–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Tsai CJ, Li J, Gonzales-Angulo AM, Allen PK, Woodward WA, Ueno NT, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER-2 directed therapy. Am J Clin Oncol. 2015;38(3):242–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from National Cancer Database. J Clin Oncol. 2014;32:2018–24.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Hennessy BT, Gonzales-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106:1000–6.

    Article  PubMed  Google Scholar 

  66. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor and HER2 defined subtypes. Ann Oncol. 2014;25:384–91.

    Article  CAS  PubMed  Google Scholar 

  67. Bauer RL, Busch E, Levine F, Edge SB. Therapy for inflammatory breast cancer: impact of doxorubicin based therapy. Ann Surg Oncol. 1995;2:288–94.

    Article  CAS  PubMed  Google Scholar 

  68. Koh EH, Buzdar AU, Ames FC, Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined modality approach – M.D. Anderson Cancer Center Experience. Cancer Chemother Pharmacol. 1990;27:94–100.

    Article  CAS  PubMed  Google Scholar 

  69. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined modality treatment of inflammatory breast cancer. Twenty years experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321–9.

    Article  CAS  PubMed  Google Scholar 

  70. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92:1775–82.

    Article  CAS  PubMed  Google Scholar 

  71. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel significantly improves the prognosis in ER negative inflammatory breast cancer. The M.D. Anderson Cancer Center Experience (1974–2000). Breast Cancer Res Treat. 2002;76 suppl 1:S158a.

    Google Scholar 

  72. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center Experience. Surg Oncol Clin N Am. 1995;4:715–34.

    Article  CAS  PubMed  Google Scholar 

  73. Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, et al. Evolving treatment strategies for inflammatory breast cancer: a population based survival analysis. J Clin Oncol. 2005;23:1941–50.

    Article  PubMed  Google Scholar 

  74. Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2010;28:83–91.

    Article  CAS  PubMed  Google Scholar 

  75. Cristofanilli M, Fratarcangeli T, Esteva F, Rosales M, Booser D, Ibrahim M, et al. Weekly high dose paclitaxel has significant antitumor activity in inflammatory breast cancer (IBC). Proceeding of the ECCO 11. Eur J Cancer. 2001;37:S173.

    Article  Google Scholar 

  76. Green MC, Buzdar AU, Smith T, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q3 wk) P therapy (tx) followed by FAC- final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol. 2002;21:35a.

    Google Scholar 

  77. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27:2938–45.

    Article  PubMed  Google Scholar 

  78. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer: pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–8.

    Article  CAS  PubMed  Google Scholar 

  79. Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Barón AE, Ross M, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998;16:1661–8.

    Article  CAS  PubMed  Google Scholar 

  80. Dazzi C, Cariello A, Rosti G, Tienghi A, Molino A, Sabbatini R, et al. Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study. Haematologica. 2001;86:523–9.

    CAS  PubMed  Google Scholar 

  81. Viens P, Palangie T, Janvier M, Fabbro M, Roché H, Delozier T. First-line high-dose sequential chemotherapy with r-GCSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 Trial). Br J Cancer. 1999;81:449–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr. Prognostic ındicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004;10:1839–48.

    Article  Google Scholar 

  83. Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML. The use of high dose cyclophosphamide, carmustine, and thitepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transpl. 2004;10:794–804.

    Article  CAS  Google Scholar 

  84. Viens P, Tarpin C, Roche H, Bertucci F. Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience. Cancer. 2010;116(11 suppl):2829–36.

    Article  CAS  PubMed  Google Scholar 

  85. Veyret C, Levy C, Chollet P, Merrouche Y, Roche H, Kerbrat P. Inflammatory breast cancer outcome with epirubicin based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer. 2006;107:2535–44.

    Article  CAS  PubMed  Google Scholar 

  86. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II or III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2014;33:13–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. von Minkwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase II trial. Lancet Oncol. 2014;15:747–56.

    Article  CAS  Google Scholar 

  88. Untch M, Schneeweiss A, Salat C, Rezai M, Zahm D-M, Klare P, et al. 163PD-long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Ann Oncol. 2017;28(suppl 5):v43–67.

    Google Scholar 

  89. Poggio F, Bruzzone M, Ceppi M, Ponde NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497–508.

    CAS  PubMed  Google Scholar 

  90. Castrellon AB, Pidhorecky I, Valero V, Raez LE. The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer. Oncol Rev. 2017;11(324):7–11.

    CAS  Google Scholar 

  91. Masuda M, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59.

    Article  CAS  PubMed  Google Scholar 

  92. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW. Prognostic significance of HER2 status in women with inflammatory breast cancer. Cancer. 2008;112:97–103.

    Article  Google Scholar 

  93. Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of human epidermal growth factor like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2.014 IBC cases from the California Cancer Registry. Breast Cancer Res. 2009;11:R9.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5 fluorouracil, epirubicin and cyclophosphamide chemotherapy and concurrent trastuzumab in HER2 positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228–33.

    Article  CAS  PubMed  Google Scholar 

  95. Cristofanilli M. Novel targeted therapies in inflammatory breast cancer. Cancer. 2010;116(11 suppl):2837–9.

    Article  CAS  PubMed  Google Scholar 

  96. Dawood S, Gonzales Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the MD Anderson experience. Cancer. 2007;110:1195–200.

    Article  CAS  PubMed  Google Scholar 

  97. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer. 2010;116:2856–67.

    Article  CAS  PubMed  Google Scholar 

  98. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, et al. Trastuzumab in primary inflammatory breast cancer, high pathologic response rates and improved outcome. Breast J. 2010;16:529–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006;24:1831–8.

    Article  CAS  PubMed  Google Scholar 

  100. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003;4:348–53.

    Article  PubMed  Google Scholar 

  101. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER-2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.

    Article  CAS  PubMed  Google Scholar 

  102. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER-2-positive locally advanced breast cancer (the NOAH trial): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15:640–7.

    Article  CAS  PubMed  Google Scholar 

  103. Baselga J, Semiglazov V, Manikhas GM, et al. Efficacy of neoadjuvan trastuzumab in patients with inflammatory breast cancer: data from the NOAH (neoadjuvant herceptin) phase III trial (abstract 2030)(ECCO meeting 2007). Eur J Cancer. 2007;5:193.

    Article  Google Scholar 

  104. Hall PS, Hanby A, Cameron DA. Lapatinib for inflammatory breast cancer. Lancet Oncol. 2009;10:538–9.

    Article  PubMed  Google Scholar 

  105. Cristofanelli M, Boussen J, Baselga J, et al. Phase II combination study of lapatinib and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer. Breast Cancer Res Treat. 2006;100:1A. Abstract

    Google Scholar 

  106. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol. 2010;28:3248–55.

    Article  CAS  PubMed  Google Scholar 

  107. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG44): a randomised phase III trial. Lancet Oncol. 2012;13:135–44.

    Article  CAS  PubMed  Google Scholar 

  108. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2 positive early breast cancer (NeoALTTO). A randomized, open label, multicentre phase III trial. Lancet. 2012;379:633–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Azambuja E, Holmes AP, Piccart M, Holmes E, Di Cosimo S, Swaby F, et al. Lapatinib with trastuzumab for HER2 positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15:1137–46.

    Article  PubMed  CAS  Google Scholar 

  110. Clavarezza M, Puntoni M, Gennari A, Paleari L, Provinciali N, D’Amico M, De Censi A. Dual block with Lapatinib and Trastuzumab versus single-agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER-2 positive breast cancer: a meta-analysis of randomized trials. Clin Cancer Res. 2016;22(18):4594–603.

    Article  CAS  PubMed  Google Scholar 

  111. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicentre, open label phase 2 trial. Lancet Oncol. 2012;13:25–32.

    Article  CAS  PubMed  Google Scholar 

  112. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomised phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278–84.

    Article  CAS  PubMed  Google Scholar 

  113. Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res. 2014;20:5359–64.

    Article  CAS  PubMed  Google Scholar 

  114. Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, Harbeck N. WSG ADAPT- West German Study Group Adjuvant Dynamic Marker Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013;14:261. https://doi.org/10.1186/1745-6215-14-261.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Küemmel S, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of WSG-ADAPT HER2+/HR- trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Ann Oncol. 2017;28:2768–72.

    Article  CAS  PubMed  Google Scholar 

  116. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktaş B, Denkert C, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomized, phase 3 trial. Lancet Oncol. 2016;17:345–56.

    Article  CAS  PubMed  Google Scholar 

  117. Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktaş B, Denkert C, et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. 2017;28:497–504.

    Article  CAS  PubMed  Google Scholar 

  118. Rubovszky G, Horvath Z. Recent advances in the neoadjuvant treatment of breast cancer. J Breast Cancer. 2017;20:119–31.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Wuerstlein R, Harbeck N. Neoadjuvant therapy for HER-2 positive breast cancer. Rev Recent Clin Trials. 2017;12:81–92.

    Article  CAS  PubMed  Google Scholar 

  120. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31.

    Article  Google Scholar 

  121. Riawi MF, Aleixo SB, Rozas AA. Nunes de Matos Neto J, Caleffi M, Figueira AC, et al. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin Breast Cancer. 2015;15(2):101–9.

    Article  CAS  Google Scholar 

  122. Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kümmel S, et al. Dual blockade with afatinib and trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy-DAFNE (GBG-70). Clin Cancer Res. 2015;21(13):2924–31. ©2015 AACR

    Article  CAS  PubMed  Google Scholar 

  123. Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans WF, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375:11–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Jacops SA, Robidoux A, Garcia JMP, Abraham J, La Verde N, Orcutt JM, et al. Abstract PD5–04: NSABP FB-7: a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer. Cancer Res. 2016;76(4 suppl):Abstract nr PD5–04.

    Google Scholar 

  125. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19:115–26.

    Article  CAS  PubMed  Google Scholar 

  126. Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, et al. De-escalation strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the West German Study Group Adjuvant Dynamic Marker Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early BC HER2 and HR-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant Trastuzumab Emtansine with or without endocrine therapy (ET) versus Trastuzumab plus ET. J Clin Oncol. 2017;35:3046–54.

    Article  CAS  PubMed  Google Scholar 

  127. Yamauchi H, Cristofanilli M, Nakamura S, Hortobaghy GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol. 2009;6:387–94.

    Article  CAS  PubMed  Google Scholar 

  128. Monneur A, Bertucci F, Viens P, Gonçalves A. Systemic treatment of inflammatory breast cancer: an overview. Bull Cancer. 2014;101:1080–8.

    PubMed  Google Scholar 

  129. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769–77.

    Article  CAS  PubMed  Google Scholar 

  130. Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, et al. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2 negative inflammatory breast cancer (BEVERLY-1): a multicentre, single arm, phase II study. Lancet Oncol. 2016;17:600–11.

    Article  CAS  PubMed  Google Scholar 

  131. Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2 positive breast cancer (BEVERLY-2): an open-label, single-arm phase II study. Lancet Oncol. 2012;13:375–84.

    Article  CAS  PubMed  Google Scholar 

  132. Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, et al. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin Cancer Res. 2015;21(6):1298–304.

    Article  CAS  PubMed  Google Scholar 

  133. Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, et al. Circulating tumor cells and pathologic complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicenter phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol. 2017;28:103–9.

    PubMed  Google Scholar 

  134. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015;17:2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  135. Palazzo A, Dellapasqua S, Munzone E, Bagnardi V, Mazza M, Cancello G, et al. Phase II trial of bevacizumab plus weekly paclitaxel, carboplatin, and metronomic cyclophosphamide with or without trastuzumab and endocrine therapy as preoperative treatment of inflammatory breast cancer. Clin Breast Cancer. 2018;18(4):328–35. https://doi.org/10.1016/j.clbc.2018.01.010.

    Article  CAS  PubMed  Google Scholar 

  136. Nahleh ZA, Dodoo C, Dwivedi AK, Botrus G. A meta-analysis of randomized controlled trials comparing the effect of neoadjuvant chemotherapy with or without bevacizumab (Bev) in the treatment of breast cancer (BC). J Clin Oncol. 2016;34(15_ suppl):577.

    Article  Google Scholar 

  137. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res. 2007;13:5862–8.

    Article  CAS  PubMed  Google Scholar 

  138. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85:1765–7.

    Article  CAS  PubMed  Google Scholar 

  139. Sakai R, Kagawa S, Yamasaki Y, Kujima T, Uno F, Hashimoto Y, et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol Cancer Ther. 2010;9:1884–93.

    Article  CAS  PubMed  Google Scholar 

  140. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol. 2007;18:1021–9.

    Article  CAS  PubMed  Google Scholar 

  141. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832–8.

    PubMed  Google Scholar 

  142. Andreopoulou E, Vigoda IS, Hershman DL, Hershman DL, Raptis G, Vahdat LT, et al. Phase I-II study of farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen-receptor positive breast carcinoma. Breast Cancer Res. 2013;141:429–35.

    Article  CAS  Google Scholar 

  143. Krisnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, et al. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus. 2013;2:409.

    Article  CAS  Google Scholar 

  144. Robertson FM, Petricoin EF III, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, et al. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. Springerplus. 2013;2:497.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  145. Stover DG, Bell CF, Tolaney SM. Neoadjuvant and adjuvant chemotherapy considerations for triple-negative breast cancer. Am J Hematol Oncol. 2016;12:6–12.

    Google Scholar 

  146. Pettitt SJ, Lord CJ. PARP inhibitors and breast cancer: highlights and hang-ups. Expert Rev Precis Med Drug Dev. 2018;3:83–94.

    Article  Google Scholar 

  147. Dua I, Tan AR. Immunotherapy for triple-negative breast cancer: a focus on ımmune checkpoint inhibitors. Am J Hematol Oncol. 2017;13:20–7.

    Google Scholar 

  148. Polk A, Svane IM, Andersson M, Nielsen D. Checkpoint inhibitors in breast cancer-curent status. Cancer Treat Rev. 2018;63:122–34.

    Article  CAS  PubMed  Google Scholar 

  149. Harvey HA, Lipton A, Lawrence BV, White DS, Wells SA, Blumenschein G, et al. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol. 1982;21:42–4.

    Article  CAS  PubMed  Google Scholar 

  150. Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006;12:5047–54.

    Article  CAS  PubMed  Google Scholar 

  151. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, et al. Statin use in primary inflammatory breast cancer: a cohort study. BJC. 2013;109:318–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–34.

    Article  CAS  PubMed  Google Scholar 

  153. Dushkin H, Cristofanilli M. Inflammatory breast cancer. J Natl Compr Cancer Netw. 2011;9(2):233–40; quiz 241

    Article  Google Scholar 

  154. Woodward WA, Buchholz TA. Unpublished observations from Yamauchı H, Woodward WA, Valero V, et al. inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012;17:891–9.

    Article  PubMed  PubMed Central  Google Scholar 

  155. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;3:961–5.

    Article  CAS  Google Scholar 

  156. Senkus E, Kyriakides S, Penault-Llorca P, Poortmans P, Thompson A, Zackrisson S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(supplement 6):vi7–23.

    PubMed  Google Scholar 

  157. Matro JM, Cristofanilli M, Hughes ME, Hughes ME, Ottesen RA, Weeks JC, et al. Inflammatory breast cancer management in the National Comprehensive Cancer Network: the disease, recurrence pattern, and outcome. Clin Breast Cancer. 2015;15:1–7.

    Article  PubMed  Google Scholar 

  158. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, et al. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018;124:2299–305.

    Article  PubMed  Google Scholar 

  159. Guler N, Karabulut B, Koçdor MA, et al. Locally advanced breast cancer-2010 Istanbul breast cancer consensus meeting. J Breast Health. 2011;7:68–89.

    Google Scholar 

  160. van Golen KL, Cristofanilli M. The third international inflammatory breast cancer conference. Breast Cancer Res. 2013;15:318.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztaj L, Bertucci F, et al. Scientific summary from the Morgan Welch MD Anderson Cancer Center ınflammatory breast cancer (IBC) program 10th anniversary conference. J Cancer. 2017;8:3607–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Retired Member of the Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Nilüfer Güler

Authors
  1. Nilüfer Güler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nilüfer Güler .

Editor information

Editors and Affiliations

  1. Oncology Institute, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Abdullah Igci

  3. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Women’s Hospital of UPMC, Pittsburgh, PA, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Güler, N. (2019). Systemic Therapy for Inflammatory Breast Cancer. In: Aydiner, A., Igci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-16792-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16792-9_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16791-2

  • Online ISBN: 978-3-030-16792-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation